Trials Sponsors Conditions Drugs Pricing

Conditions

Dry Eye Disease

Keywords

Ocular SurfaceTear FilmLiposomal NanocarrierOphthalmic Formulation

Outcome Measures

Primary Outcomes (1)

Change in protocol-defined multidomain ocular-surface clinical assessment profile
The exploratory protocol assessed ocular-surface and tear-film response using a predefined examination panel rather than a single confirmatory efficacy endpoint. The panel included corneal fluorescein staining, conjunctival lissamine-green staining, fluorescein tear break-up time, Schirmer I testing without topical anaesthesia, OCT-derived tear-meniscus height, Ocular Surface Disease Index, intraocular pressure, central corneal thickness, LIPCOF, visual acuity, slit-lamp examination, and posterior-segment assessment. The record intentionally does not retrospectively designate one of these measures as the sole primary efficacy endpoint.
Baseline to end of the approximately 4-week use period

Secondary Outcomes (1)

Change in optical tear-film parameters in the nested optical substudy
Baseline to approximately 4 weeks

Other Outcomes (1)

Diary-documented administration of the study formulation
Throughout the 28-day study-use period

Study Arms (1)

Experimental liposomal nanocarrier

EXPERIMENTAL

Participants instilled the experimental ophthalmic liposomal nanocarrier bilaterally for four weeks.

Other: Experimental ophthalmic liposomal nanocarrier

Interventions

Experimental ophthalmic liposomal nanocarrierOther

One drop was instilled into each eye three times daily (morning, midday, and evening) for four weeks.

Experimental liposomal nanocarrier

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Adults aged 18 years or older with dry eye disease diagnosed by an ophthalmologist.
Written informed consent.

Sponsors & Collaborators

Regional Specialist Hospital in Wroclaw
Otherlead

Study Sites (1)

Regional Specialist Hospital in Wroclaw

Wroclaw, 51-124, Poland

MeSH Terms

Conditions

Dry Eye Syndromes

Condition Hierarchy (Ancestors)

Lacrimal Apparatus DiseasesEye Diseases

Enrollment

26 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: OTHER
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 25, 2026

First Posted

August 28, 2026

Study Start

March 17, 2022

Actual (reported)

Four-Week Ocular-Surface Evaluation of an Experimental Ophthalmic Liposomal Nanocarrier in Dry Eye Disease

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Other Outcomes (1)

Study Arms (1)

Experimental liposomal nanocarrier

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Other Outcomes (1)

Study Arms (1)

Experimental liposomal nanocarrier

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations